Skip to main content

Table 2 Clinical and parasitological outcomes

From: Implementation and evaluation of a quality and safety tool for ambulatory strongyloidiasis patients at high risk of adverse outcome

  Pre-implementation (n = 26) Post-implementation (n = 11) p-value
Seroreversionc (%)
 Yes 8 (42.1) 5 (62.5)  
 No 11 (57.9) 3 (37.5)a 0.420
Clearance of Stool larval shedding (%)
 Yes 4 (80.0) 3 (100.0)  
 No 1 (20.0) 0 (0) 1.000
Loss to follow-up (%)
 Yes 6 (23.1) 2 (20.0)  
 No 20 (76.9) 8 (80.0)b 1.000
  1. aOne patient not assessible
  2. bOne patient not assessible
  3. cdefined as a two-thirds reduction in baseline serologic optical density